Dietary Intervention Improves Gastrointestinal Symptoms after Treatment of Cancer in the Pelvic Organs.

Gastrointestinal (GI) symptoms are common in patients receiving radiotherapy, chemotherapy, and/or surgery for cancer in the pelvic organs. The aim of the present prospective cohort study was to report the efficacy of dietary intervention in patients with chronic GI sequelae to treatment of cancer in pelvic organs and insufficient symptomatic effect of medical treatment. Eighty-eight patients were offered specialist dietitian guidance.

[Gastrointestinal late sequelae to cancer treatment of the pelvic organs].

Late sequelae to cancer treatment of the pelvic organs are common. Gastrointestinal symptoms including chronic diarrhoea, faecal urgency, and faecal incontinence are some of the most disabling with a negative impact on quality of life. By investigating and treating the gastrointestinal symptoms in specialised late adverse effects clinics more than half of the patients can be helped.

Management of treatment-related sequelae following colorectal cancer.

Aim: Colorectal cancer survivors are one of the most rapidly growing groups of patients living with and beyond cancer. In a national multidisciplinary setting, we have examined the extent of late treatment-related sequelae in colorectal cancer survivors and present the scientific evidence for management of these conditions in this patient category with the aim of facilitating identification and treatment.

Method: A systematic search for existing guidelines and relevant studies was performed across 16 and 4 databases, respectively, from inception to 2021.

Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.

Background: Data from real-life populations about vedolizumab as first-line biological therapy for ulcerative colitis (UC) and Crohn's disease (CD) are emerging.

Objective: To investigate the efficacy and safety of vedolizumab in bio-naïve patients with UC and CD.

Methods: A Danish nationwide cohort study was conducted between November 2014 and November 2019.

[Symptoms of diabetic gastroenteropathy in patients with diabetes].

Abdominal pain, nausea, vomiting, diarrhoea, constipation, and faecal incontinence are common symptoms of diabetic gastroenteropathy and often have a major impact on quality of life. The symptoms are usually caused by widespread dysfunction of the gastrointestinal tract. Hence, diagnosis requires panenteric assessment.

Sacral Nerve Modulation Has No Effect on the Postprandial Response in Irritable Bowel Syndrome.

Purpose: Irritable bowel syndrome is a common gastrointestinal disorder with a global prevalence of approximately 11%. Onset or worsening of symptoms following digestion is one of the characteristics of the condition. The present study aimed at evaluating the postprandial sensory and motor response before and after treatment with sacral nerve modulation.

Implications of rectal preconditioning for interpretation of sensory-motor data.

Testing of biomechanical properties of intestine requires the tissue to be preconditioned by applying cyclic loading to obtain repeatable mechanical data. However, little is known about the mechanosensory properties during intestinal preconditioning. We aimed to study the relationship between mechanical preconditioning of the human rectum and sensory response.

Sacral nerve modulation for irritable bowel syndrome: A randomized, double-blinded, placebo-controlled crossover study.

Background: Irritable bowel syndrome (IBS) is among the most common gastrointestinal disorders, and a substantial proportion of patients have an insufficient response to treatment. In a single-blinded study, sacral nerve modulation (SNM) significantly reduced symptoms of IBS. The aim of the present double-blinded, randomized, placebo-controlled study was to evaluate the effect of SNM for IBS.

Clinical evaluation and treatment of chronic bowel symptoms following cancer in the colon and pelvic organs.

Chronic gastrointestinal symptoms are common among patients surviving surgery and/or radio-/chemotherapy for cancer in the pelvic organs. However, little is known about the pathophysiology behind symptoms or the effect of treatment. The aim of the present study was to present the results of clinical evaluation and treatment of patients with chronic bowel symptoms after treatment for cancer in the colon or pelvic organs.

[Nutrition and dietary supplement in chronic inflammatory bowel diesease].

Nutrition and food items may improve or worsen symptoms in Crohn's disease and ulcerative colitis. Protein malnutrition and vitamin and mineral deficiencies are common, particularly deficiency of iron and vitamin D. Dietary fibres and omega-3 fatty acids are safe, but no evidence supports their use as treatment.

Constipation in adults with neurofibromatosis type 1.

Background: Neurofibromatosis type 1 (NF1) is an autosomal-dominant disease characterised by symptoms of the skin, eyes, nervous system and bones. A previous study indicated that constipation, large rectal diameters and prolonged colorectal transit times are common in children with NF1. The aim of the present study was to investigate and compare the prevalence of gastrointestinal symptoms in adult patients with NF1 to their unaffected relatives serving as the control group.

Danish national guideline: Diagnosis and treatment of Irritable Bowel Syndrome.

National Danish guidelines for the diagnosis and treatment of irritable bowel syndrome (IBS) in adult patients in secondary and tertiary care have been approved by the Danish Society for Gastroenterology and Hepatology. IBS can be a positive diagnosis in patients fulfilling the Rome III criteria for IBS with no alarm signals, a normal physical examination and a normal CRP and hemoglobin. In patients < 40 years with IBS and diarrhea, a normal fecal calprotectin excludes inflammatory bowel disease with a high probability.

[Irritable bowel treatment].

More than every tenth Dane have irritable bowel syndrome. The condition is diagnosed by a positive strategy including fulfilment of the Rome III criteria, absence of alarm symptoms, and if needed a few paraclinical tests. Currently, there is no cure of the disorder.

A randomised, controlled study of small intestinal motility in patients treated with sacral nerve stimulation for irritable bowel syndrome.

Background: Irritable bowel syndrome (IBS) is among the most common gastrointestinal disorders worldwide. In selected patients with severe diarrhoea-predominant or mixed IBS subtypes sacral nerve stimulation (SNS) alleviates IBS-specific symptoms and improves quality of life. The mode of action, however, remains unknown.

A randomized, controlled, crossover study of sacral nerve stimulation for irritable bowel syndrome.

Objective: To investigate whether sacral nerve stimulation reduces irritable bowel syndrome (IBS)-specific symptoms by a randomized, controlled, crossover study.

Background: IBS affects 3% to 22% of the population worldwide, but most patients continue to have symptoms despite treatment.

Methods: Patients included from our tertiary center had diarrhea-predominant or mixed IBS, with a minimum baseline IBS symptom score (Gastrointestinal Syndrome Rating Scale-IBS questionnaire) of 40 points reduced by a minimum of 30% during the percutaneous nerve evaluation before permanent implantation.

Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer.

Background And Purpose: Preoperative radiotherapy for rectal cancer has a detrimental effect on long-term anorectal function and quality of life, additional to that observed after rectal resection. The exact physiological mechanisms for the excess impairment remain unknown. We aimed to investigate neorectal and anal sphincter properties in patients treated with neoadjuvant therapy (NT) prior to total mesorectal excision (TME).